Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

PRECISION ImmunoRad Personalized molecular reprogramming of the tumor immune microenvironment and engineered adoptive cell transfer in synergy with ion-beam radiotherapy for next-generation curative cancer treatments

Coordinator
Universitatsklinikum Heidelberg, Germany
Runs
1 June 2026 to 31 May 2032
Status
Running
EU funding
€14.0m
Total cost
€14.0m
Partners
4 organisations in 3 countries
Type
European Research Council grant
Grant agreement
101225200

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is a complex multifaceted disease. To conquer cancer, a multidisciplinary approach for rational design of multimodal therapies is imperative. Ground-breaking discoveries in immunotherapy and precision radiotherapy (RT) coupled with initial encouraging results of their combined application, have engendered hope that curative cancer treatments may become possible. Our objective is to harness the full synergistic potential of both modalities through deeper comprehension of the tumor immune microenvironment (TIME) evolution in response to therapy selection pressures.

We propose innovative strategies to overcome five major obstacles limiting immunotherapy success: i) tumor camouflage from immune cell recognition, ii) limited immune cell homing and tumor trafficking, iii) paucity of immune activating signals, iv) suppressive signals in the TIME, and v) failure to induce deep memory responses for durable antitumor immunity. The convergence of four research fields, each represented by pioneering scientists, provides a unique opportunity to revolutionize current cancer treatment.

To reprogram TIME and create an immunopermissive tumor niche we will employ a broad spectrum of clinical-grade ion beams including protons, helium-, carbon-, and oxygen ions with unique biophysical properties. These novel beam qualities, combined with targeted molecular countermeasures against key tumor immune evasive mechanisms, such as interference with TGFbeta- and integrated stress response pathways, will establish an effective in situ cancer vaccination strategy.

In synergy with RT-mediated TIME reprogramming, two adoptive immune cell therapies will be explored: personalized vaccine-induced T cells targeting tumor-specific intracellular neoantigens and chimeric antigen receptor (CAR) T cells engineered to specifically recognize tumor membrane-associated antigens. Our team is uniquely positioned worldwide to develop the next generation of precision immunoradiotherapy.

Topics

Who is involved

OrganisationCityCountryRole
Universitatsklinikum HeidelbergHeidelbergGermanyCoordinator
Cyprus Cancer Research InstituteNicosiaCyprusParticipant
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
The Trustees of the University of Pennsylvania CorpPhiladelphiaUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI